drugset / Trial / NCT00048152
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.
Timeline
- Start
- 2000-12
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | — | — |
| Subject | Daclizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 1 g | Oral |
Indications
No indication recorded.